HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vegetable Oil Sterol Esters Heart Disease Claim Sought By Lipton

This article was originally published in The Tan Sheet

Executive Summary

Spreads and salad dressings bearing a proposed health claim for vegetable oil sterol esters (VOSE) and a reduced risk of heart disease should be exempted from "total fat" and "low fat" disqualifying levels, Lipton urges FDA in a citizen petition recently made available by the agency. Certain levels of fat and cholesterol can prevent an otherwise qualified product from being able to use a health claim.

You may also be interested in...



FDA Expands Phytosterol Heart Health Claim In Proposed Rule

FDA significantly overhauls a health claim linking phytosterols to a reduced risk of coronary heart disease, expanding the type of enriched conventional foods and forms of dietary supplements that can make the claim.

Benecol, Take Control Marketing Highlight Approved CHD Health Claims

McNeil Consumer Healthcare's Benecol spread will soon be carrying labeling stating it can reduce the risk of coronary heart disease, the company said. The new labeling follows FDA's Sept. 8 approval of McNeil's health claim petition.

Plant Stanol Esters Enhance Rx Cholesterol Drugs - McNeil Petition

Foods and dietary supplements containing plant stanol esters augment the cholesterol-lowering effects of several Rx drugs, McNeil Consumer Healthcare states in a health claim petition recently made available by FDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel